Trial | NCT04653077  Report issue

Title

MSCs Therapy for Cerebral Palsy
Bone Marrow Stem Cells Transplantation for the Treatment of Cerebral Palsy

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    50
Cerebral palsy (CP) is the most common physical disability in childhood. CP comprises a heterogeneous group of disorders that are the result of a non-progressive disruption or injury that occurred during fetal brain development or within the first two years of life.
This disruption can result in spasticity, dystonia, muscle contractures, weakness and difficulty in coordination that ultimately affects the ability to control movements. Resultant activity limitations may affect gross motor movements, fine motor movements, speech and communication, as well as eating and drinking.
Study Started
Dec 02
2020
Anticipated
Primary Completion
Oct 15
2022
Anticipated
Study Completion
Dec 01
2022
Anticipated
Last Update
Dec 04
2020

Other stem cells

Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.

stem cells Experimental

Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.

Criteria 

Inclusion Criteria:

• Must be more than 2 year of age and less than 12 years of age at the time of screening for inclusion in the study.

Clinical evidence of a non-progressive motor disability due to brain dysfunction.

Exclusion Criteria:

• Intractable seizures

Traumatic brain injury
Genetic disorder
Current Infection
Renal insufficiency
Hepatic disease
HIV+ (as demonstrated by positive blood test)
Immunosuppression
No Results Posted